Why Earnings Season Could Be Great for Boise Cascade (BCC)
Investors are always looking for stocks that are poised to beat at earnings season Boise Cascade Company BCC may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Boise Cascade is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for BCC in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at 57 cents per share for BCC, compared to a broader Zacks Consensus Estimate of 45 cents per share. This suggests that analysts have very recently bumped up their estimates for BCC, giving the stock a Zacks Earnings ESP of +27.61% heading into earnings season.
Boise Cascade, L.L.C. Price and EPS Surprise
Boise Cascade, L.L.C. Price and EPS Surprise | Boise Cascade, L.L.C. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that BCC has a Zacks Rank #1 (Strong Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Boise Cascade, and that a beat might be in the cards for the upcoming report.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boise Cascade, L.L.C. (BCC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
